-
CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer
The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, introduced significant updates to the 2025 edition of the CSCO Breast Cancer Guidelines (CSCO BC Guidelines). Among the most notable changes was a revision in the treatment approach for patients with HER2-low breast cancer. Oncology Frontier invited Professor Ying Yan from…
-
NCCN 2025 | Professor Jihong Liu: Strengthening Management and Monitoring Adverse Events in Immunotherapy-Chemotherapy for Endometrial Cancer
Endometrial cancer is one of the most common gynecologic malignancies, with its global incidence on the rise. In recent years, immunotherapy combined with chemotherapy has emerged as a promising strategy, demonstrating significant benefits in prolonging survival and maintaining durable responses in patients with advanced or recurrent endometrial cancer. However, as the use of immuno-chemotherapy becomes…
-
ELCC 2025 | Professor Keith Kerr Receives the Heine H. Hansen Award
At the European Lung Cancer Congress (ELCC), the prestigious Heine H. Hansen Award was presented to Professor Keith Kerr, a pathologist from the Aberdeen Royal Infirmary, in recognition of his outstanding contributions to oncology research. The announcement was made by ELCC co-chairs Professor Enrico Ruffini, a thoracic surgeon from the Università di Torino, and Professor…
-
ELCC Co-Chair, Professor Enrico Ruffini Highlights Key Differences in Surgical Management Strategies for Thymoma and Thymic Carcinoma
At the 2025 European Lung Cancer Congress (ELCC), Professor Enrico Ruffini, thoracic surgeon at the Università di Torino and Co-Chair of the ELCC, delivered a dedicated presentation titled “Thymoma and thymic carcinoma: Different surgical management strategies?” During the conference, Oncology Frontier had the opportunity to speak with Professor Ruffini for an in-depth discussion on the…
-
Darolutamide and PSA Response: New Insights from ARANOTE at EAU25
Presented at the 40th Annual EAU Congress, the ARANOTE study offered valuable post hoc insights into the significance of PSA response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated…
-
Professor Qingguo Li : Advancing Minimally Invasive Techniques to Preserve Function and the Anus in Low Rectal Cancer
Oncology Frontier: At this year’s meeting, you gave an excellent presentation on the development of an expert consensus for the prevention and management of Low Anterior Resection Syndrome (LARS) in…
-
Professor Xue Yang: ADC Research Updates from the 2025 ELCC Conference
Oncology Frontier：What new ADC data were presented at the 2025 ELCC in the field of first-line and later-line lung cancer treatment? Professor Xue Yang:：In the field of later-line treatment, one…
-
Post-ASCO GI 2025 | Professors Kefeng Ding and Ying Yuan Discuss the BBCAPX Study: A New Path Forward in Immunotherapy for RAS-Mutant/MSS Unresectable
Following the presentation, Professor Kefeng Ding joined Professor Yuan in a dialogue reflecting on the key progress of the study and its future direction, rekindling hope for immunotherapy in this…
Connecting Medical Expertise through Media